Stockreport

Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study [Seeking Alpha]

Upstream Bio, Inc.  (UPB) 
PDF Verekitug's once-every-12-weeks dosing offers competitive differentiation versus standard of care and existing biologics like Tezspire. Upcoming UPB catalysts include [Read more]